Sign In
Buy ARCT
$5.76
-0.160 (-2.70%)
At Close: Jul 31, 2026
Arcturus Gears Up to Report Q3 Earnings: Here's What to Expect
11:05am, Monday, 04'th Nov 2024
On ARCT's third-quarter 2024 earnings call, investors' focus is likely to be on the upcoming launch of its COVID-19 vaccine, Kostaive and other pipeline updates.
Arcturus Therapeutics (ARCT) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Wednesday, 30'th Oct 2024
Arcturus Therapeutics (ARCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty
11:51am, Tuesday, 01'st Oct 2024
Arcturus stock gains as the company reports that its sa-mRNA COVID-19 vaccine, ARCT-154, shows superior efficacy compared with treatment with Comirnaty.
Head-to-head data, presented at OPTIONS XII for the Control of Influenza Conference, demonstrates advantage of sa-mRNA over conventional mRNA in duration of immune response; Results highlight CSL and
Here's Why Investors Should Invest in Arcturus Stock Now
12:31pm, Monday, 16'th Sep 2024
Here, we are discussing some reasons why investing in ARCT stock now may turn out to be a prudent move.
New Strong Buy Stocks for September 13th
08:16am, Friday, 13'th Sep 2024
ARCT, MHO, FMBH, PAM and ANGO have been added to the Zacks Rank #1 (Strong Buy) List on September 13, 2024.
Approval underscores CSL and Arcturus Therapeutics' commitment to delivering disruptive technologies to combat COVID-19 and other respiratory viral diseases to protect public health KOSTAIVE®, the wo
Does Arcturus Therapeutics (ARCT) Have the Potential to Rally 216.35% as Wall Street Analysts Expect?
10:55am, Monday, 02'nd Sep 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 216.4% in Arcturus Therapeutics (ARCT). While the effectiveness of this highly sought-after metric is questiona
What Makes Arcturus Therapeutics (ARCT) a New Strong Buy Stock
01:01pm, Friday, 23'rd Aug 2024
Arcturus Therapeutics (ARCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Buy Stocks for August 23rd
08:20am, Friday, 23'rd Aug 2024
RHHBY, SBSI, FCCO, APELY and ARCT have been added to the Zacks Rank #1 (Strong Buy) List on August 23, 2024.
High-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive Vaccine
05:27am, Friday, 09'th Aug 2024
Arcturus is close to launching the Kostaive COVID-19 vaccine in Japan, with ongoing work on variant protection and influenza vaccine. The company has been able to consistently derive research revenues
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2024 Earnings Call Transcript
08:50pm, Monday, 05'th Aug 2024
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q2 2024 Earnings Call Transcript August 5, 2024 4:30 PM ET Company Participants Neda Safarzadeh - VP, Head of IR, Public Relations and Marketing Joe
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates
06:10pm, Monday, 05'th Aug 2024
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $1.85. This compares to loss of $1.98 per share a year ago.
Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress
04:01pm, Monday, 05'th Aug 2024
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the deve
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024
07:30pm, Thursday, 18'th Jul 2024
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the deve
